Polyrizon Ltd. (PLRZ)
NASDAQ: PLRZ · Real-Time Price · USD
11.50
+0.08 (0.70%)
At close: Jun 26, 2026, 4:00 PM EDT
11.48
-0.02 (-0.17%)
After-hours: Jun 26, 2026, 4:10 PM EDT
Polyrizon Employees
As of December 31, 2025, Polyrizon had 4 total employees, including 2 full-time and 4 part-time employees. The number of employees decreased by 2 or -33.33% compared to the previous year.
Employees
4
Change (1Y)
-2
Growth (1Y)
-33.33%
Revenue / Employee
n/a
Profits / Employee
-$833,750
Market Cap
21.49M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 4 | -2 | -33.33% |
| Dec 31, 2024 | 6 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Pluri | 142 |
| Celularity | 115 |
| Longeveron | 38 |
| Palatin Technologies | 29 |
| Lipocine | 14 |
| Tvardi Therapeutics | 12 |
| Cellectar Biosciences | 11 |
| VYNE Therapeutics | 10 |
PLRZ News
- 11 days ago - Polyrizon gets patent for Trap & Target mucoadhesive polymer technology platform - TheFly
- 11 days ago - Polyrizon Receives Notice of U.S. Patent Publication for Mucoadhesive Drug Delivery Platform - GlobeNewsWire
- 13 days ago - Polyrizon Advances NASARIX™ Development with Key Human Study to Characterize Nasal Residence Time and Support FDA Regulatory Pathway - GlobeNewsWire
- 18 days ago - Polyrizon receives notice of European patent publication - TheFly
- 18 days ago - Polyrizon Receives Notice of European Patent Publication for Innovative Mucoadhesive Nasal Drug Delivery Technology - GlobeNewsWire
- 20 days ago - Polyrizon signs agreements with two additional clinical sites for Nasarix study - TheFly
- 20 days ago - Polyrizon Makes Strong Clinical Progress: Secures Three U.S. Sites for NASARIX™ Trial - GlobeNewsWire
- 6 weeks ago - Polyrizon signs clinical trial agreement with clinical research site for Nasarix - TheFly